Positive Phase III SANOVO trial results at #ESMO26: 1L ORPATHYS® + TAGRISSO® reduced risk of progression or death by 44% overall and 55% in high MET overexpression, with encouraging OS benefit (HR=0.48) in this treatment-naïve biomarker-selected patients. https://hutch-med.com/esmo26-sanovo/